Cancer stem cells (CSC) are thought to play a major role in the development and metastatic progression of pancreatic ductal adenocarcinoma (PDAC), one of the deadliest solid tumors. Likewise, the tumor microenvironment contributes critical support in this setting, including from tumor stromal cells and tumor-associated macrophages (TAM) that contribute structural and paracrine-mediated supports, respectively. Here we show that TAM secrete the interferon-stimulated factor ISG15 which enhances CSC phenotypes in PDAC in vitro and in vivo. ISG15 was preferentially and highly expressed by TAM present in primary PDAC tumors resected from patients. ISG15 was secreted by macrophages in response to secretion of interferon-β; by CSC, thereby reinforcing CSC self-renewal, invasive capacity and tumorigenic potential. Overall, our work demonstrates that ISG15 is a previously unrecognized support factor for CSC in the PDAC microenvironment with a key role in pathogenesis and progression.
INTRODUCTION
The importance of the stroma in promoting cancer initiation and solid tumor growth has been increasingly recognized during recent years (1) (2) (3) . Specifically, we have come to understand that apart from providing structural support for tumor development, the tumor-associated microenvironment of many solid tumors provides cues to a subpopulation of tumor-initiating cells, also known as cancer stem cells (CSCs), which regulates their self-renewal, tumorigenic and metastatic potential (4) . This is certainly the case for pancreatic adenocarcinoma (PDAC), which consists of a heterogeneous population of tumor cells including (i) CSCs (5, 6) , (ii) more differentiated cancer cells and (iii) an extremely high proportion of desmoplastic stromal tissue and immune cells, which accounts for up to 90% of the tumor mass (7) . Within the stroma-rich PDAC tumor microenvironment, pancreatic stellate cells (PSCs) have been extensively studied and recent reports from our laboratory and other have shown that tumor-associated PSCs can create a pro-tumor paracrine niche for PDAC CSCs via Nodal/ActivinA secretion (2, 4) . Recent but less conclusive evidence also suggests that inflammatory cells, such as tumor-associated macrophages (TAMs) (1, 8) may also play critical roles in the development and progression of numerous tumors, such as PDAC, and the immuno-modulatory factors they secrete may also be paracrine-mediated.
Interferon-stimulated gene 15 (ISG15) is a 165 amino acid (17kDa) protein that is induced by Type I interferon (IFN) treatment (9) . Since its discovery in 1979 (10), ISG15 has been extensively studied as an anti-viral protein (11) (12) (13) , but we now appreciate that ISG15 has many other functions, including ISGylation, a ubiquitin-like modification process whereby ISG15 can be covalently linked to cytoplasmic and nuclear proteins (14) . Like ubiquitin, ISG15 coupling to target proteins involves the ISG15-specific E1-like activating enzyme (UbE1L), the conjugating E2 enzyme and the ligating E3 enzymes (15, 16) . While the consequences of ISGylation of host proteins has been elucidated for only a small set of cellular proteins (e.g. cyclin D1, Filamin B, PML-RARα), it is believed that the biological effects of ISGylation are dynamic and cell type/tissue specific (17) . For example, while some reports suggest that like ubiquitilation, ISGylation may function in protein turnover (18) , it may also play a previously unrecognized role in protein stability (17) . The latter has been explored in systems of bladder, oral, prostate and breast cancers, where high levels of ISG15 and its conjugates have been detected, suggesting a link between ISG15 and tumorigenesis (19) (20) (21) (22) (23) (24) . For example, Kiessling et al have shown that in prostate cancer, over expression of UbE1L increased androgen receptor levels in an ISG15-dependent manner, implying that ISGylation promotes androgen receptor over expression in cancer cells. In breast cancer, Burks et al have shown that ISG15 stabilizes oncogenic K-ras protein by inhibiting its targeted degradation via lysosomes. Therefore, intracellular ISGylation may very well play an important and previously underappreciated role in cancer.
Apart from its intracellular protein conjugating functions, ISG15 can also be secreted from cells as free ISG15 where it can act as a cytokine or chemokine stimulating the production of Type II IFN, enhancing natural killer cell activity and proliferation or functioning as a strong neutrophil chemoattractant (25, 26) . Thus, free ISG15 has strong immune modulatory properties; however, the biological role of free ISG15 has been under studied and the mechanisms promoting its liberation are poorly understood. Surprisingly, here we show that ISG15 is present in PDAC tumors, it is expressed and secreted by TAMs in response to IFN-β produced by PDAC cells and, in turn, acts on PDAC CSCs enhancing their inherent "stem-like" properties, including selfrenewal and tumorigenicity. Thus, our data suggests a previously unrecognized role for ISG15 (i.e. free ISG15) in the context of pancreatic cancer and highlights a potentially new target for therapeutic intervention.
MATERIALS AND METHODS
Primary pancreatic cancer cells and macrophages. The use of human material was approved by the local ethics committee of each respective hospital or university, and written informed consent was obtained from all patients. Primary tumors were processed, cultured in vitro as previously detailed (5) and are referred to herein as "Panc-xxx". Murine PDAC cells were established from tumors extracted from K-ras+/LSL-G12D;Trp53LSL-R172H;PDX1-Cre mice (27) at 20-24 weeks of age.
Human blood was obtained from healthy donors with informed consent and in accordance with national regulations for the use of human samples in research. Macrophages were established as previously described (28) and polarized using 1000 U/ml GM-CSF (M2) or M-CSF (M1) (29) .
Murine monocytes were isolated from mechanically disrupted spleens and polarized using 10 ng/ml of IFN-γ (PeproTech) and LPS (Sigma) (M1) or 10 ng/ml IL-4 (M2) (PeproTech). HPDE cells have been previously described (30) .
Human PDAC Tissue microarrays (TMAs) and RNA samples. Human TMAs containing a total of 42 tumors were constructed. RNA from 30 flash-frozen primary human PDAC tumors was isolated by the guanidine thiocyanate method using standard protocols (31 numbers of non-polarized, M1-or M2-polarized, or CSC CM-primed primary macrophages. Tumor size was monitored weekly over the course of 6-10 weeks.
ELISAs. IFN-β in the supernatant of PDAC cultures was quantified using a commercially available ELISA (PBL Assay Science) as per the manufacturer's instructions. Free ISG15 was quantified using an in-house sandwich ELISA as detailed in Supplemental Materials and Methods.
Immunohistochemistry and immunofluoresecnce. Formalin-fixed paraffin-embedded (FFPE) blocks were serially sectioned and immunohistochemical (IHC) or immunfluorescence (IF) analyses performed using standard protocols. Primary antibodies, secondary antibodies and dilutions used are detailed in Table S1 .
RNA preparation and RTqPCR. Total RNA was isolated by the guanidine thiocyanate method using standard protocols (31) . cDNA synthesis was performed using the QuantiTect Reverse Transcription Kit (Qiagen, Barcelona, Spain), followed by SYBR green RTqPCR (Applied Biosystems). Primers used are listed in Table S2 .
Sphere formation assay. Pancreatic cancer spheres were generated as previously described (4).
Wound healing assay. Confluent cultures of primary cancer cells seeded were scratched using a 200µl pipette tip after overnight starvation. Cells were then incubated at 37°C with indicated treatments.
Statistical analyses.
Results for continuous variables are presented as means ± standard error of the mean (SEM) unless stated otherwise. Treatment groups were compared with the independent samples t test. Pair-wise multiple comparisons were performed with the one-way ANOVA (twosided) with Bonferroni adjustment. P values<0.05 were considered statistically significant. All analyses were performed using SPSS 17.0 (SPSS Inc., Chicago, IL).
Additional experimental procedures and details can be found in the Supplemental Materials and Methods section.
Macrophages promote PDAC CSC self-renewal, migration and tumorigenesis. Apart from neutrophils, infiltrating macrophages represent one of the major immune cell types present in the high stroma-rich PDAC tumor microenvironment (32) (Fig. S1A) . Thus, since it has been shown in other solid tumors that CSC properties can be promoted by microenvironmental factors (33, 34) , we aimed to test whether macrophage-secreted factors could also enhance PDAC CSC phenotypes. Since macrophages are not static, but rather are highly plastic and can be differentially polarized into classically "activated"/"M1" macrophages or "alternativelyactivated", "M2" or "pro-tumorigenic" macrophages (reviewed in (35)), we therefore tested the effects of both M1 and M2 macrophages on PDAC CSCs. First, the self-renewal capacity of two different primary PDAC cultures was assessed by culturing Panc354 and Panc185 cells in anchorage independent conditions and in the presence of control media or conditioned media from M1-polarized or M2-polarized monocyte-derived macrophages. First and second generation sphere formation increased when cells were cultured in the presence of macrophage-conditioned media by ~1.5-to 2-fold, with the greatest increase observed when PDAC cells were cultured with conditioned media from M2-polarized macrophages (Fig. 1A) . In addition, we also observed an increase in the expression of the pluripotency-associated genes Klf4, Sox2, and Nanog, modulation of EMT-associated genes e-cadherin, Zeb-1 and vimentin (Fig. 1B) , enhancement of the migratory capacity of PDAC cells when co-cultured with conditioned media from M2-polarized macrophages (Fig. 1C) , and activation of pErk1/2, a mediator of pro-survival and proproliferation pathways, in treated sphere cultures (Fig. 1D) .
Macrophages can also respond to cues from cancer cells and differentiate towards a protumorigenic "M2" phenotype in response to tumor micro-environmental stimuli such as CSF1, IL-4, IL-13, TGFβ1 or IL-10 (36). Therefore, we additionally treated macrophages with conditioned media harvested from PDAC spheres, which are enriched in CSCs ( pattern similar to that of macrophages polarized with GM-CSF to an M2 phenotype (Fig. 1E) .
Likewise, media removed from these CSC-primed macrophages was also able to enhance PDAC sphere formation, promote the expression of pluripotency-associated genes and increase PDAC cell migration similar to conditioned media from non-CSC primed MCSF-treated M2-polarized macrophages ( Fig. 1A-B and data not shown).
Lastly, we injected 5×10 5 primary PDAC cells alone or with equal numbers of M1-polarized, M2-polarized or CSC conditioned media-primed primary human macrophages and assessed tumor growth over 8 weeks. Consistent with the aformentioned in vitro data, tumor growth was significantly accelerated when PDAC cells were co-injected with M2 macrophages or with macrophages pre-stimulated (i.e. "primed") with media from CSC spheres ( Fig. 1F and S2) .
Thus, the sum of these data would suggest that an intricate and intimate crosstalk exists between
CSCs and macrophages, where CSCs promote the polarization of macrophages towards an M2-like phenotype, which can then, in turn, promote the "stemness" and tumorgenicity of CSCs.
Macrophages increase the expression and secretion of ISG15 when co-cultured with PDAC CSCs. We next co-cultured monocyte-derived macrophages with and without primary PDAC cells in transwells. Seventy-two hours post co-culture, RNA was extracted from macrophages and microarray analyses were performed. 3,084 genes were significantly upregulated and 3,431 genes downregulated (FDR<0.05) compared to control cultures. Of the top 25-upregulated genes (FDR<10 -4 , ⏐logFC⏐>2), the majority of genes belonged to the family of interferon-stimulated genes (ISGs) ( Fig. 2A) . Of the 19 ISGs detected, we focused on ISG15 as a gene of potential interest as it encodes for a protein than can function intra-cellularly to modify cytoplasmic and nuclear proteins, it can also be secreted from activated cells as free ISG15, and ISG15 has been shown to play a putative role in other solid tumors such as bladder, oral, prostate and breast cancers (19) (20) (21) (22) (23) (24) . We confirmed the microarray results by RTqPCR and WB analysis. conditioned media we observed a strong increase in ISG15 mRNA and protein levels (conjugated and monomeric) compared to non-treated control macrophage cultures ( Fig. 2B-C) .
We also observed an increase in the ISG15 de-conjugating enzyme USP18 ( Fig. 2A-B) , which functions to remove ISG15 from its conjugates, thus increasing the overall amount of monomeric ISG15 (37) . We hypothesized that the increased amount of monomeric ISG15 present in macrophages treated with PDAC CSC-conditioned sphere media (Fig. 2C) would result in increased secretion of free ISG15. In accordance with this hypothesis, we observed an increase in free ISG15 in the supernatant of treated macrophages compared to non-treated controls (Fig. 2D) .
M2-polarized macrophages alone secreted more ISG15 compared to M1-polarized macrophages, and free ISG15 levels could be further and significantly enhanced by first priming macrophages with conditioned sphere media from two different primary cultures of PDAC CSC spheres (Fig.   2D ).
These results strongly suggested that PDAC CSC conditioned sphere medium must contain Type I IFNs, a potent stimulus of ISG15 expression (9) . Since it has been shown that Kras-transformed breast cancer tumors over express IFN-β (38), we next determined if PDAC CSCs also produce/secrete IFNβ and whether it is biologically active using an ELISA for IFNβ and a vesicular stomatitis virus (VSV)-based anti-viral assay, respectively. Both assays confirmed that PDAC CSCs (e.g. spheres) secrete IFNβ (Fig. 2E) , it is biologically active (Fig. 2F) and it is the likely causative factor for the ISG15 activation observed in monocyte-derived macrophages.
To study the effect of macrophage-derived free ISG15 release on PDAC cells, we analyzed intracellular ISG15 levels (conjugated and non-conjugated) in adherent PDAC cultures and in CSC sphere cultures left untreated or treated with conditioned media from 48h CSCprimed control, M1-or M2-polarized macrophages. Independent of treatment, intracellular monomeric and extracellular free ISG15 levels were significantly higher in CSC-enriched spherederived cultures compared to adherent cultures, which contain more differentiated cancer cells (Fig. 2G-H medium, we observed a specific increase in intracellular ISGylation levels and a corresponding decrease in the non-conjugated form of ISG15, indicating that the high levels of free ISG15 released by M2 macrophages (Fig. 2D) act on PDAC CSCs, further enhancing the conjugation of monomeric ISG15 to target proteins (Fig. 2G) . However, unlike macrophages, we did not observe differences in the levels of free ISG15 in the supernatant of PDAC cultures following treatment (Fig. 2H) . Interestingly, the levels of the de-conjugating enzyme USP18 were low to undetectable in PDAC cultures as determined by RTqPCR analysis (data not shown), providing a possible explanation as to why these cells secrete little free ISG15, even after stimulation.
Primary PDAC tumors express ISG15. To assess whether ISG15 could represent an important mediator of cancer development, we first studied the relationship between ISG15 expression and cancer survival at the genomic level. Using various publically available microarray datasets from PrognoScan (http://www.abren.net/PrognoScan/), a database for metaanalysis of the prognostic value of genes (39), we found that across several tumor entities, higher expression of ISG15 was predictive of significantly lower overall survival (Fig. 3A-B) . Since no PDAC datasets are publically available, we evaluated the expression of ISG15 by RT-qPCR in bulk PDAC tumor samples obtained from ~ 30 surgical resections and by immunohistochemical (IHC) analysis using PDAC tissue microarrays. Compared to four normal pancreas controls, overexpression of ISG15 mRNA was observed in the majority of PDAC samples evaluated (Fig.   3C ). Regarding its expression at the protein level, we observed that ISG15 was expressed in ~95% of all the tumors analyzed; however, distinct differences were observed with respect to the level and type of cells expressing ISG15 (Fig. 3D) . For example, while ISG15 expression was detected in neoplastic cells of ~17% of tumors, ISG15 was predominantly expressed by immune cells (e.g. TAMs) in the stroma of PDAC tumors (Fig. 3D-E, S3, S4 and S5A) . This was not the case for other tumors such as breast cancer and prostate cancer, in which tumor cells express the majority of ISG15 (Fig. S5B-C) . 
ISG15 promotes CSC phenotypes. Since macrophages can secrete free ISG15 and since macrophage-conditioned media enhances the "stemness" of PDAC CSCs (Fig. 1) , we reasoned that ISG15 might be a pro-CSC factor secreted by macrophages in response to cues from PDAC CSCs (e.g. IFN-β). To test this hypothesis, PDAC cultures were treated with recombinant ISG15 (rISG15). The 1 st generation sphere-forming capacity of CSCs from three primary PDAC cultures increased with rISG15 treatment compared to control-treated cultures (Fig. 4A) , and the effect was more pronounced during serial passaging, which further enriches for CSCs (4) . The increase in sphere formation also correlated with an overall increase in the expression of pluripotencyassociated genes in Panc354 spheres treated with rISG15 during serial passaging compared to untreated cultures (Fig. 4B) . In addition, rISG15 treatment also increased the migratory capacity of sphere-derived cells in a standard wound healing assay as shown in Fig. 4C . Lastly, similar to what we observed with M2 macrophage conditioned media (Figs. 1D and 2G ), rISG15 treatment of CSCs also increased the level of intracellular ISGylation (Fig. 4D ) and the phosphorylation of the pro-survival protein Erk1/2 (Fig. 4E) . Taken together, these data strongly suggest that ISG15 alone can potentiate the "stemness" of CSCs and thus, macrophages likely potentiate CSCs, in part, via an ISG15-mediated mechanism.
To further validate our findings, we took advantage of mice with a genetic inactivation of the ISG15 gene. Using murine monocyte-derived macrophages, isolated from ISG15 knockout mice, we show that compared to ISG15 +/+ M2-polarized macrophages, the conditioned medium from ISG15 -/-M2-polarized macrophage cultures did not similarly enhance murine PDAC sphere formation (Fig. 5A) , the expression of stemness genes (Fig. 5B) , their migratory capacity in a wound healing assay (Fig. S6) , or the phosphorylation of Erk1/2 (Fig. 5D) (Fig. 5E) , indicating that the lack of secreted ISG15 is responsible for the impaired ability of ISG15 -/-cells to promote PDAC tumor growth in vivo.
While these data strongly suggested that a driving factor responsible for PDAC tumorigenesis is ISG15, we next performed a limiting dilution cell transplantation assay to more rigorously determine the effect of ISG15 on the frequency of CSC-initiated tumor formation in 
DISCUSSION
TAMs, also known as M2, "alternatively-activated" or "pro-tumorigenic" macrophages [reviewed in (35) ], are the major cell type of the inflammatory infiltrates present in PDAC tumors (32, 40) and are believed to promote tumorigenesis, matrix remodeling, and metastasis (36, 41, 42) . In accordance with the latter, we observed that compared to M1 macrophages, M2 macrophages were able to promote the self-renewal capacity, modulate the expression of pluripotency-and EMT-associated genes, increase the migratory potential and enhance the tumorigenic capacity of PDAC CSC in a contact-independent manner. It is important to note, however, that we cannot discard the fact that human PDAC cells injected into nude mice may have activated murine macrophages to secrete pro-tumor factors. Thus, the effects observed with human PDAC cells in nude mice may have cross-species contributions.
At the cellular level, primary human macrophages that were treated with conditioned media from PDAC CSC cultures acquired M2-like properties at the level of cell morphology (data not shown) and expression of M2 cell surface markers, such as CD163, and media from these cultures enhanced the "stem-like" properties of PDAC CSCs similar to that of M2 macrophages. Thus, our data confirm that macrophages, specifically "M2/alternatively activated" macrophages, can significantly modulate the properties of PDAC CSCs via secreted factors, and PDAC CSCs can promote the polarization of macrophages towards an M2 phenotype. It is worth noting that the PDAC tumor microenvironment is composed of many other cell types, including T-cells, neutrophils and PSCs, which can also positively influence the "stemness" of PDAC CSCs as well as TAMs. Thus, the effects we observe in vitro are likely an under representation of the cross-talk that exists within the more complex multi-cellular tumor niche in vivo.
While macrophages can secrete many pro-stimulatory factors, we indentified by microarray analysis that ISG15 and its de-conjugating enzyme USP18 were highly up-regulated in macrophages co-cultured with PDAC CCSs. This apparent over expression was not all that inducer of ISG15, and our IFN-β ELISA and VSV anti-viral assays both confirmed that PDAC cells produce soluble and biologically active IFN-β. Interestingly, a growing body of evidence over the past few years has shown a link between ISG15 and tumorigenesis for several solid tumors (19) (20) (21) (22) (23) (24) . The general conclusion from these studies is that ISG15 is over expressed in many tumor cell lines and ISGylation is important for malignant transformation; however, the mechanism(s) by which ISG15 exerts its pro-tumor effects and whether ISG15 functions the same in all solid cancer entities is still unknown. In line with these studies, our retrospective analysis of Our model depicted in Fig. 6 illustrates how ISG15 is regulated within the PDAC tumor. Unfortunately, the receptor for ISG15 is currently unknown. It is believed that free ISG15 acts via binding to a cell surface receptor rather than passive diffusion into the cell; however, until a receptor is discovered, this question remains a black box. Regarding how ISG15 exerts its effect(s), in this study we show for the first time that rISG15 can activate p44/42 MAPK (ERK1/2) signaling, a pathway that has been shown to be important for cancer cells. Appreciating that other pathways may also be modulated by ISG15, we are currently investigating whether the AKT-PI3K and mTOR/S6K pathways, both of which have been shown to be important in PDAC (44, 45) , are also affected by free ISG15. Along these lines, previous work from our laboratory has shown a direct link between AKT signaling and ISG15 in macrophages (11) . We have reported that ISG15 plays an important role in the regulation of macrophage functions as ISG15 -/-macrophages display reduced activation, phagocytic capacity and programmed cell death activation in response to vaccinia virus infection. This phenotype is independent of cytokine production and secretion, but correlates with impaired activation of the protein kinase AKT in 
Lastly, we cannot currently separate the fact that intracellular ISGylation is likely also an active and important process in PDAC cells. The purpose of our study was to investigate the role of TAM-secreted factors on PDAC CSC features, and thus we primarily focused on the effects of free ISG15 on PDAC CSCs, rather than the role of intracellular ISG15 and ISGylated products.
Our data do, however, suggest that macrophages increase intracellular ISGylation in PDAC CSCs via secreted free ISG15. Thus, apart from activation of p44/42 MAPK (ERK1/2) signaling in PDAC CSCs, it may very well be that another important mechanisms of action of TAM-derived free ISG15 is to potentiate the conjugation of intracellular ISG15 to its target host proteins in PDAC CSCs, a process that has been shown to be beneficial for cancer cells of other tumor entities (22) (23) (24) , but which has not been shown or studied to date in PDAC. 
